medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2018, Number S1

<< Back Next >>

Acta Med 2018; 16 (S1)

Chronic kidney disease and pregnancy

Orozco GA

Language: Spanish
References: 25
Page: 41-46
PDF size: 131.63 Kb.


ABSTRACT

This review describes the evolution of chronic kidney disease (CKD) during pregnancy. Three to four per cent of all fertile young women have CKD in different stages. Women in developed countries delay pregnancy and, thus, have an increased risk of CKD. There is a large group of fertile women with subclinical CKD, which is important and difficult to detect. CKD is frequently associated with risk factors such as hypertension, diabetes, autoimmune diseases, obesity, renal transplant and others. CKD is classified according to glomerular filtration rate (GFR) in three stages: mild (stages 1-2), GFR › 60 mL/min; moderate (stages 3a and 3b), GFR 30-60 mL/min; and severe (stage 4), GFR ‹ 30 and › 15 mL/min. All stages corrected for 1.73 m2BS. It is important to comment that all women with CKD are prone to a decrease in the renal function during pregnancy. In these cases, it is important to control the blood pressure and proteinuria, as well as to maintain a constant renal function six months before pregnancy. A good control of these clinical variables before and during gestation prevents premature deliveries, low-weight products, and preeclampsia or eclampsia. Birth control is advised with caution in high-risk patients with CKD. Experts should evaluate and treat pregnant patients in need of dialysis.


REFERENCES

  1. Cietak KA, Newton JR. Serial qualitative maternal nephrosonography in pregnancy. Br J Radiol. 1985; 58 (689): 399-404.

  2. Rasmussen PE, Nielsen FR. Hydronephrosis during pregnancy: a literature survey. Eur J Obstet Gynecol Reprod Biol. 1988; 27 (3): 249-259.

  3. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63 (5): 713-735.

  4. Abe S. Pregnancy in IgA nephropathy. Kidney Int. 1991; 40 (6): 1098-1102.

  5. Abe S. The influence of pregnancy on the long-term renal prognosis of IgA nephropathy. Clin Nephrol. 1994; 41 (2): 61-64.

  6. Liu Y, Ma X, Lv J, Shi S, Liu L, Chen Y et al. Risk factors for pregnancy outcomes in patients with IgA nephropathy: a matched cohort study. Am J Kidney Dis. 2014; 64 (5): 730-736.

  7. Limardo M, Imbasciati E, Ravani P, Surian M, Torres D, Gregorini G et al. Pregnancy and progression of IgA nephropathy: results of an Italian multicenter study. Am J Kidney Dis. 2010; 56 (3): 506-512.

  8. Young EC, Pires ML, Marques LP, de Oliveira JE, Zajdenverg L. Effects of pregnancy on the onset and progression of diabetic nephropathy and of diabetic nephropathy on pregnancy outcomes. Diabetes Metab Syndr. 2011; 5 (3): 137-142.

  9. Rossing K, Jacobsen P, Hommel E, Mathiesen E, Svenningsen A, Rossing P et al. Pregnancy and progression of diabetic nephropathy. Diabetologia. 2002; 45 (1): 36-41.

  10. Piccoli GB, Cabiddu G, Attini R, Vigotti FN, Maxia S, Lepori N et al. Risk of adverse pregnancy outcomes in women with CKD. J Am Soc Nephrol. 2015; 26 (8): 2011-222.

  11. Haas DM, Sabi F, McNamara M, Rivera-Alsina M. Comparing ambulatory spot urine protein/creatinine ratios and 24-h urine protein measurements in normal pregnancies. J Matern Fetal Neonatal Med. 2003; 14 (4): 233-236.

  12. Fischer MJ, Lehnerz SD, Hebert JR, Parikh CR. Kidney disease is an independent risk factor for adverse fetal and maternal outcomes in pregnancy. Am J Kidney Dis. 2004; 43 (3): 415-423.

  13. Munkhaugen J, Lydersen S, Romundstad PR, Widerøe TE, Vikse BE, Hallan S. Kidney function and future risk for adverse pregnancy outcomes: a population-based study from HUNT II, Norway. Nephrol Dial Transplant. 2009; 24 (12): 3744-3750.

  14. Koetje PM, Spaan JJ, Kooman JP, Spaanderman ME, Peeters LL. Pregnancy reduces the accuracy of the estimated glomerular filtration rate based on Cockroft-Gault and MDRD formulas. Reprod Sci. 2011; 18 (5): 456-462.

  15. Côté AM, Lam EM, von Dadelszen P, Mattman A, Magee LA. Monitoring renal function in hypertensive pregnancy. Hypertens Pregnancy. 2010; 29 (3): 318-329.

  16. Smith MC, Moran P, Ward MK, Davison JM. Assessment of glomerular filtration rate during pregnancy using the MDRD formula. BJOG. 2008; 115 (1): 109-112.

  17. Masuyama H, Nobumoto E, Okimoto N, Inoue S, Segawa T, Hiramatsu Y. Superimposed preeclampsia in women with chronic kidney disease. Gynecol Obstet Invest. 2012; 74 (4): 274-281.

  18. Kristensen K, Larsson I, Hansson SR. Increased cystatin C expression in the pre-eclamptic placenta. Mol Hum Reprod. 2007; 13 (3): 189-195.

  19. Côté AM, Firoz T, Mattman A, Lam EM, von Dadelszen P, Magee LA. The 24-hour urine collection: gold standard or historical practice? Am J Obstet Gynecol. 2008; 199 (6): 625.e1-625.e6.

  20. Kyle PM, Fielder JN, Pullar B, Horwood LJ, Moore MP. Comparison of methods to identify significant proteinuria in pregnancy in the outpatient setting. BJOG. 2008; 115 (4): 523-527.

  21. Leaños-Miranda A, Márquez-Acosta J, Romero-Arauz F, Cárdenas-Mondragón GM, Rivera-Leaños R, Isordia-Salas I et al. Protein: creatinine ratio in random urine samples is a reliable marker of increased 24-hour protein excretion in hospitalized women with hypertensive disorders of pregnancy. Clin Chem. 2007; 53 (9): 1623-1628.

  22. Piccoli GB, Conijn A, Attini R, Biolcati M, Bossotti C, Consiglio V et al. Pregnancy in chronic kidney disease: need for a common language. J Nephrol. 2011; 24 (3): 282-299.

  23. Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation. 1996; 94 (3): 483-489.

  24. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT; Prevention of Renal and Vascular End Stage Disease Study Group. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med. 2001; 161 (16): 2000-2005.

  25. Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013; 87 (1): 93-100.




2020     |     www.medigraphic.com